PPARA and type 2 diabetes mellitus: Despite the clinical failures of some dual-PPAR agonists due to notable side effects, other multi-target PPAR activators, especially chiglitazar, saroglitazar, elafibranor, and lanifibranor, are quickly picking up the pace and have displayed outstanding efficacy in T2DM, dyslipidemia, NAFLD, and PBC.